Additionally, despite the absence of in silico evidence of a relevant modulation of aromatase and ERα, CBG and CBN were included in our study, as some studies in different tumors, including triple-negative breast cancer, have pointed out their therapeutic potential as anti-cancer compounds [75,76]. This evidence concerns the gene CYP19A1 and cancer.